AstraZeneca (AZN)

Advertisement

Just one of over 6000 shares you can deal on with IG. Find out more by getting your free guide to spread betting on shares. Losses can exceed your initial deposit

3,383.00p
   
  • Change Today:
    -6.50p
  • 52 Week High: 3,396.00
  • 52 Week Low: 2,591.00
  • Currency: UK Pounds
  • Shares Issued: 1,251.39m
  • Volume: 2,121,350
  • Market Cap: £42,334m
  • RiskGrade: 66
  • Beta: 0.65

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart

6 Month Chart

AstraZeneca Financials

Latest F'cast
Div Yield 5.5% 5.4%
Div Cover 2.3 1.9
Op Mrgn 29.1% 26.9%
ROCE 74.6%  
Latest F'cast
P/E 8.0 10.0
PEG n/a n/a
Pr/Revenue 2.3 2.5
Pr/Book 2.7  
Latest F'cast
Revenue -16.7% -60.0%
PBT -37.6% -60.9%
EPS -12.0% -19.1%
DPS n/a -57.6%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-08 31,601.00 8,681.00 510.00¢ 8.4 0.5 +16% 205.00¢ 4.8%
31-Dec-09 32,804.00 10,807.00 632.00¢ 7.0 0.3 +24% 230.00¢ 5.2%
31-Dec-10 33,269.00 10,977.00 671.00¢ 6.6 1.1 +6% 255.00¢ 5.8%
31-Dec-11 33,591.00 12,367.00 728.00¢ 6.2 0.8 +8% 280.00¢ 6.2%
31-Dec-12 27,973.00 7,718.00 641.00¢ 6.9 n/a -12% 280.00¢ 6.3%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-13 16,972.58 4,572.93 337.90p 10.0 n/a -19% 180.03p 5.4%
31-Dec-14 16,472.35 4,574.06 324.36p 10.4 n/a -4% 182.69p 5.5%

Copyright © 2013 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

Director/PDMR Shareholding 14-May-2013 14:00 RNS
Director/PDMR Shareholding 08-May-2013 14:00 RNS
Director/PDMR Shareholding 08-May-2013 14:00 RNS

AstraZeneca ShareCast News

Monday broker round-up UPDATE 29-Apr-2013 ShareCast
Monday newspaper round-up: BP, AstraZeneca, Sain... 29-Apr-2013 ShareCast
Friday tips round-up: Admiral, AstraZeneca 26-Apr-2013 ShareCast

AstraZeneca Motley Fool Analysis & Commentary

A Closer Look At AstraZeneca Plc's Dividend Pote... 14-May-2013 Motley Fool
Is AstraZeneca Plc The Ultimate Stock-Pickers Sh... 2013--29 Motley Fool
Will I regret selling AstraZeneca plc? 2013--23 Motley Fool

AstraZeneca Top Newspaper Links

AstraZeneca staff find new jobs ahead of plant c... 30-Dec-2011 Telegraph
AstraZeneca back on top with new drug deals 22-Dec-2011 Daily Mail
ASTRAZENECA TURNS TO ASIA 22-Dec-2011 Express & Star

Latest AstraZeneca Director Deals

Traded Action Notifier PriceAmountValue
07-May-13 Transfer From Simon Lowth 0.000p 12,955 £0.00
29-Apr-13 Sell Simon Lowth 3,328.00p 8,690 £289,203.19
26-Apr-13 Buy Prof Dame Nancy Rothwell 3,320.00p 238 £7,901.60

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 3,383.00p
Change Today -6.50p
% Change -0.19 %
52 Week High 3,396.00
52 Week Low 2,591.00
Volume 2,121,350
Shares Issued 1,251.39m
Market Cap £42,334m
Beta 0.65
RiskGrade 66

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
72.57% above the market average72.57% above the market average72.57% above the market average72.57% above the market average72.57% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Price Trend
40.42% above the market average40.42% above the market average40.42% above the market average40.42% above the market average40.42% above the market average
44.00% above the sector average44.00% above the sector average44.00% above the sector average44.00% above the sector average44.00% above the sector average
Income
93.19% above the market average93.19% above the market average93.19% above the market average93.19% above the market average93.19% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
94.12% below the market average94.12% below the market average94.12% below the market average94.12% below the market average94.12% below the market average
94.87% below the sector average94.87% below the sector average94.87% below the sector average94.87% below the sector average94.87% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 22
Sell 4
Strong Sell 6
Total 38
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 13-Feb-13 08-Aug-12
Paid 18-Mar-13 10-Sep-12
Amount 190.00¢ 90.00¢

Trades for 17-May-2013

Time Volume / Share Price
16:53 375,000 @ 3,374.17p
16:44 4 @ 3,383.00p
16:41 5,307 @ 3,381.93p
16:41 200 @ 3,384.50p
16:39 6,723 @ 3,383.00p

AstraZeneca Key Personnel

CEO Pascal Soriot

Top of Page